Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method

被引:10
|
作者
Manduru, M
Mihm, LB
White, RL
Friedrich, LV
Flume, PA
Bosso, JA
机构
[1] MED UNIV S CAROLINA,COLL PHARM,QF 218,ANTIINFECT RES LAB,CHARLESTON,SC 29425
[2] MED UNIV S CAROLINA,COLL MED,DEPT MED,CHARLESTON,SC 29425
[3] MED UNIV S CAROLINA,COLL MED,DEPT PEDIAT,CHARLESTON,SC 29425
关键词
D O I
10.1128/AAC.41.11.2527
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Bactericidal activity, historically assessed by in vitro tests which employ fixed drug concentrations, may also be evaluated in in vitro pharmacodynamic models in which in vivo pharmacokinetics and bacterial growth conditions can be simulated, However, systematic comparisons between the two methods are lacking, We evaluated the bactericidal activities of ceftazidime, at two different concentration/MIC ratios (C/MICs), against 10 clinical isolates of Pseudomonas aeruginosa in a two-compartment model with continuous-infusion conditions and a 2-h half-life. These values were compared to those determined by traditional 24-h time-kill (TTK) methods at the same C/MICs, Bactericidal activities were compared by using area under the colony count-time curves, Antibiotic exposure (area under the drug concentration-time curve) was also evaluated, Although bactericidal activity appeared greater by the TTK method (P = 0.05), when it was normalized for drug exposure, these differences disappeared (P = 0.2), This disparity was likely due to differences in drug exposure in the TTK method and in the peripheral compartment of the model (site of bacteria) over the first 8 h of the experiment, during which the antibiotic accumulated to target concentrations, This suggests that the bactericidal effects with constant antibiotic concentrations are similar in the two methods; however, this may not hold true with fluctuating drug concentrations, Further, results from the pharmacodynamic model may theoretically be more relevant, as in vivo pharmacokinetics and bacterial growth conditions can be more faithfully simulated.
引用
收藏
页码:2527 / 2532
页数:6
相关论文
共 50 条
  • [21] Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar
    Ahmed, Mazen A. Sid
    Hadi, Hamad Abdel
    Hassan, Abubaker A., I
    Abu Jarir, Sulieman
    Al-Maslamani, Muna A.
    Eltai, Nahla Omer
    Dousa, Khalid M.
    Hujer, Andrea M.
    Sultan, Ali A.
    Soderquist, Bo
    Bonomo, Robert A.
    Ibrahim, Emad Bashir
    Jass, Jana
    Omrani, Ali S.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (12) : 3497 - 3504
  • [22] Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
    Wang, Leilei
    Zhang, Xuefei
    Zhou, Xun
    Yang, Fan
    Guo, Qinglan
    Wang, Minggui
    MICROBIOLOGY SPECTRUM, 2023, 11 (03):
  • [23] In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology
    Kresken, Michael
    Koerber-Irrgang, Barbara
    Laeuffer, Joerg
    Decker-Burgard, Sabine
    Davies, Todd
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 38 (01) : 70 - 75
  • [24] In vitro bactericidal property of levornidazole against Bacteroides fragilis studied by time-kill assay and sigmoid Emax model analysis
    Hu, Jiali
    Zhang, Jing
    Chen, Yuancheng
    Wu, Shi
    Zhu, Demei
    Yang, Yang
    Zhang, Yingyuan
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (06) : 673 - 675
  • [25] An improved PKPD modeling approach to characterize the pharmacodynamic interaction over time between ceftazidime/avibactam and colistin from in vitro time-kill experiments against multidrug-resistant Klebsiella pneumoniae isolates
    Aubry, Romain
    Buyck, Julien
    Prouvensier, Laure
    Decousser, Jean-Winoc
    Nordmann, Patrice
    Wicha, Sebastian G.
    Marchand, Sandrine
    Gregoire, Nicolas
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (10)
  • [26] The evaluation of in vitro pharmacodynamic properties of amphotericin B, voriconazole and caspofungin against A-fumigatus isolates by the conventional and colorimetric time-kill assays
    Kiraz, Nuri
    Oz, Yasemin
    Dag, Ilknur
    MEDICAL MYCOLOGY, 2011, 49 (06) : 594 - 601
  • [27] In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
    Levasseur, Premavathy
    Girard, Anne-Marie
    Claudon, Monique
    Goossens, Herman
    Black, Michael T.
    Coleman, Kenneth
    Miossec, Christine
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (03) : 1606 - 1608
  • [28] Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model
    Zhuang, Luning
    Sy, Sherwin K. B.
    Xia, Huiming
    Singh, Rajendra P.
    Mulder, Midas B.
    Liu, Changxiao
    Derendorf, Hartmut
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (02) : 151 - 160
  • [29] Elucidation of the pharmacokinetic/ pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model
    Bilal, Hajira
    Peleg, Anton Y.
    McIntosh, Michelle P.
    Styles, Ian K.
    Hirsch, Elizabeth B.
    Landersdorfer, Cornelia B.
    Bergen, Phillip J.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (06) : 1570 - 1578
  • [30] Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
    Buehrle, Deanna J.
    Shields, Ryan K.
    Chen, Liang
    Hao, Binghua
    Press, Ellen G.
    Alkrouk, Ammar
    Potoski, Brian A.
    Kreiswirth, Barry N.
    Clancy, Cornelius J.
    Nguyen, M. Hong
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3227 - 3231